MX2020007467A - Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona. - Google Patents

Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona.

Info

Publication number
MX2020007467A
MX2020007467A MX2020007467A MX2020007467A MX2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A
Authority
MX
Mexico
Prior art keywords
dihydrophthalazin
amino
diona
solubilize
phosphatidylcholines
Prior art date
Application number
MX2020007467A
Other languages
English (en)
Inventor
Ingo Saar
Wolfgang Brysch
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of MX2020007467A publication Critical patent/MX2020007467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a un método para solubilizar 5-amino-2,3-dihidroftalazin-1,4-diona o sus sales, al solubilizado producido por este método, y los usos respectivos en una forma de dosificación farmacéutica. Se divulga un método de solubilización basado en fosfatidilcolinas.
MX2020007467A 2018-01-11 2019-01-10 Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona. MX2020007467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18000019.2A EP3511325A1 (en) 2018-01-11 2018-01-11 Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
PCT/EP2019/000012 WO2019137825A1 (en) 2018-01-11 2019-01-10 Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

Publications (1)

Publication Number Publication Date
MX2020007467A true MX2020007467A (es) 2020-09-14

Family

ID=61094178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007467A MX2020007467A (es) 2018-01-11 2019-01-10 Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona.

Country Status (15)

Country Link
US (2) US12122753B2 (es)
EP (2) EP3511325A1 (es)
JP (2) JP7446226B2 (es)
KR (1) KR102734983B1 (es)
CN (1) CN111587243B (es)
AU (1) AU2019207332B2 (es)
BR (1) BR112020013847A2 (es)
CA (1) CA3084113A1 (es)
ES (1) ES2952192T3 (es)
HR (1) HRP20230766T1 (es)
HU (1) HUE062433T2 (es)
IL (1) IL275193B2 (es)
MX (1) MX2020007467A (es)
PL (1) PL3737668T3 (es)
WO (1) WO2019137825A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290026A1 (en) * 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
US20210379063A1 (en) * 2018-10-26 2021-12-09 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis
WO2021091905A1 (en) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
CN115768402A (zh) 2020-03-25 2023-03-07 麦翠奥制药公司 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮
US20240075029A1 (en) 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE10133305B4 (de) 2001-07-12 2004-06-03 Aquanova German Solubilisate Technologies (Agt) Gmbh Ubichinon Konzentrat
AU2003263024A1 (en) 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
RU2245138C1 (ru) * 2003-10-21 2005-01-27 Общество с ограниченной ответственностью "Абидофарма" Способ лечения глазных заболеваний и глазные капли и глазная мазь для его осуществления
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US20080188540A1 (en) * 2007-02-05 2008-08-07 Wyeth Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2009282659A1 (en) 2008-08-18 2010-02-25 Nanotherapeutics, Inc. Topical hydrogel composition
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
EP2393361B1 (en) * 2009-02-06 2016-12-07 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
EP2243517A1 (de) * 2009-04-20 2010-10-27 Dr. Straetmans GmbH Kosmetische oder dermatologische Zubereitung
PT2542535E (pt) 2010-03-01 2014-08-25 Metriopharm Ag Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
US8871811B2 (en) 2011-02-07 2014-10-28 Professional Compounding Centers of America, Ltd Permeation enhancers for topical formulations
DK2804587T3 (da) 2012-01-19 2019-08-12 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DE202012012130U1 (de) 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
WO2016096143A1 (de) 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
EP3416951B1 (en) * 2016-02-16 2020-04-08 MetrioPharm AG Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
CA3011766C (en) * 2016-02-16 2023-08-01 Metriopharm Ag Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
EP3290026A1 (en) * 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

Also Published As

Publication number Publication date
IL275193A (en) 2020-07-30
BR112020013847A2 (pt) 2021-03-02
US20210061771A1 (en) 2021-03-04
US20250051288A1 (en) 2025-02-13
IL275193B1 (en) 2024-04-01
ES2952192T3 (es) 2023-10-30
PL3737668T3 (pl) 2023-11-27
EP3737668A1 (en) 2020-11-18
JP7762245B2 (ja) 2025-10-29
CN111587243B (zh) 2024-04-12
KR102734983B1 (ko) 2024-11-26
KR20200108864A (ko) 2020-09-21
EP3737668C0 (en) 2023-06-07
EP3737668B1 (en) 2023-06-07
JP7446226B2 (ja) 2024-03-08
JP2024059864A (ja) 2024-05-01
NZ764957A (en) 2024-07-05
US12122753B2 (en) 2024-10-22
HUE062433T2 (hu) 2023-11-28
JP2021511301A (ja) 2021-05-06
CN111587243A (zh) 2020-08-25
AU2019207332A1 (en) 2020-06-18
HRP20230766T1 (hr) 2023-10-27
IL275193B2 (en) 2024-08-01
WO2019137825A1 (en) 2019-07-18
EP3511325A1 (en) 2019-07-17
CA3084113A1 (en) 2019-07-18
AU2019207332B2 (en) 2023-09-28
RU2020118910A (ru) 2022-02-11

Similar Documents

Publication Publication Date Title
MX2020007467A (es) Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona.
DOP2022000088A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2019001337A1 (es) Formulaciones farmacéuticas.
CL2020000382A1 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática.
CO2017012893A2 (es) Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2018016362A (es) Formulaciones de anticuerpo anti-cd19.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2017005255A (es) Derivados de carbazol.
AR105089A1 (es) ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
MX2017005808A (es) Procedimiento para la preparacion de 1,4-bencenodiaminas 2-sustituidas y sales de las mismas.
CL2017003201A1 (es) Variantes de il-37
MX382616B (es) Productos y métodos para el enjuague bucal.
CY1120700T1 (el) Ενωσεις τριαμινοπυριμιδινης χρησιμες για προληψη ή αγωγη ελονοσιας
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
MX2019004579A (es) Composiciones para el cuidado bucal y metodos de uso.
CL2020001252A1 (es) Métodos de uso y composiciones que contienen dulaglutida.
AR112282A1 (es) Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.
AR114270A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmacéutico